Literature DB >> 7686320

Insulin-like growth factor (IGF) I and II and IGF binding protein (IGFBP) 1, 2 and 3 in serum from patients with Cushing's syndrome.

P Bang1, M Degerblad, M Thorén, J Schwander, W Blum, K Hall.   

Abstract

In the present study of twenty-two patients with Cushing's syndrome, serum insulin-like growth factor (IGF)-I concentrations were normal to high with an increased mean IGF-I concentration, 40% above that of healthy subjects of the same age (p < 0.001). Serum IGF-II concentrations were normal. The morning serum IGF binding protein (IGFBP)-1 concentrations were within the range of healthy controls. IGFBP-1 was inversely correlated to the IGF-I concentration (p < 0.001) and to the 24 h urinary cortisol excretion (p < 0.005) with a combined R squared value of 0.58. In contrast to IGFBP-1, serum IGFBP-2 and IGFBP-3 concentrations were elevated by 1.89 +/- 1.78 SD and 0.92 +/- 0.78 SD (mean +/- 2 SD), respectively. Although increased, the serum IGFBP-2 concentration was inversely correlated to the IGF-I concentration (r = -0.67, p < 0.001). Immunoreactive IGFBP-3 was increased in proportion to IGF-I and the molar ratio [IGFBP-3]:[IGF-I] + [IGF-II] was close to unity (1.04 +/- 0.14), as that of healthy subjects. In serum from patients with Cushing's syndrome, with increased immunoreactive IGFBP-3, there was a corresponding increase in intact glycosylated 40-43 kDa IGFBP-3 as determined by Western ligand blotting. Neutral size chromatography of serum from patients with Cushing's syndrome showed that IGF-I and IGFBP-3 immunoreactivity were predominantly found at the elution volume of the ternary 150 kDa IGF-I/IGFBP-3/acid labile subunit complex and a similar pattern was displayed by normal serum.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686320

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  7 in total

1.  Dexamethasone does not increase IGF-I and IGFBP-3 levels in man in the absence of endogenous GH.

Authors:  F E Finamor; A M Lengyel
Journal:  J Endocrinol Invest       Date:  2001-12       Impact factor: 4.256

2.  IGF-I levels rise and GH responses to GHRH decrease during long-term prednisone treatment in man.

Authors:  M H Borges; A C Pinto; F B DiNinno; C Camacho-Hübner; A Grossman; C E Kater; A M Lengyel
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

3.  Cognitive response to estradiol in postmenopausal women is modified by high cortisol.

Authors:  Laura D Baker; Sanjay Asthana; Brenna A Cholerton; Charles W Wilkinson; Stephen R Plymate; Pattie S Green; George R Merriam; Mark A Fishel; G Stennis Watson; Monique M Cherrier; Monica L Kletke; Pankaj D Mehta; Suzanne Craft
Journal:  Neurobiol Aging       Date:  2011-08-19       Impact factor: 4.673

4.  Collection of blood in heparinized tubes does not alter the molecular distribution or forms of IGFBP-3 and IGF.

Authors:  S Mandel; E Moreland; R G Rosenfeld; S E Gargosky
Journal:  Endocrine       Date:  1996-08       Impact factor: 3.633

5.  The IGF/IGFBP system in relation to macroscopic bone architecture in pediatric renal transplant patients.

Authors:  Daniela Kiepe; Eva-Maria Rüth; Werner F Blum; Subburaman Mohan; Lutz T Weber; Burkhard Tönshoff
Journal:  Pediatr Nephrol       Date:  2009-12-22       Impact factor: 3.714

6.  An unusual case of an ACTH-secreting macroadenoma with a germline variant in the aryl hydrocarbon receptor-interacting protein (AIP) gene.

Authors:  Pia T Dinesen; Jakob Dal; Plamena Gabrovska; Mette Gaustadnes; Claus H Gravholt; Karen Stals; Judit Denes; Sylvia L Asa; Márta Korbonits; Jens O L Jørgensen
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2015-01-01

7.  Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study.

Authors:  Inga-Lill Engvall; Björn Svensson; Birgitta Tengstrand; Kerstin Brismar; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2008-11-05       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.